CL2013002029A1 - Celula progenitora y no diferenciada neural humana expandible aislada; composicion que la comprende; metodo de cultivo in vitro; dicho cultivo in vitro; y su uso para tratar una condicion causada por perdida de mielina o de oligodendrocitos. - Google Patents

Celula progenitora y no diferenciada neural humana expandible aislada; composicion que la comprende; metodo de cultivo in vitro; dicho cultivo in vitro; y su uso para tratar una condicion causada por perdida de mielina o de oligodendrocitos.

Info

Publication number: CL2013002029A1
Authority: CL; Chile
Prior art keywords: vitro culture; oligodendrocytes; myelin; treat; loss
Prior art date: 2011-01-12

Application number

CL2013002029A

Other languages

English (en)

Inventor

Tsuneo Kido

Original Assignee

Tsuneo Kido

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-01-12

Filing date

2013-07-12

Publication date

2014-05-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45529155&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013002029(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-07-12 Application filed by Tsuneo Kido filed Critical Tsuneo Kido

2014-05-09 Publication of CL2013002029A1 publication Critical patent/CL2013002029A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/44—Thiols, e.g. mercaptoethanol
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/105—Insulin-like growth factors [IGF]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/135—Platelet-derived growth factor [PDGF]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
- C12N2533/32—Polylysine, polyornithine

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Biotechnology (AREA)
Neurology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Neurosurgery (AREA)
Cell Biology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Developmental Biology & Embryology (AREA)
Ophthalmology & Optometry (AREA)
Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Vascular Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Virology (AREA)

CL2013002029A 2011-01-12 2013-07-12 Celula progenitora y no diferenciada neural humana expandible aislada; composicion que la comprende; metodo de cultivo in vitro; dicho cultivo in vitro; y su uso para tratar una condicion causada por perdida de mielina o de oligodendrocitos. CL2013002029A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161431944P	2011-01-12	2011-01-12
US201161558527P	2011-11-11	2011-11-11

Publications (1)

Publication Number	Publication Date
CL2013002029A1 true CL2013002029A1 (es)	2014-05-09

Family

ID=45529155

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2013002029A CL2013002029A1 (es)	2011-01-12	2013-07-12	Celula progenitora y no diferenciada neural humana expandible aislada; composicion que la comprende; metodo de cultivo in vitro; dicho cultivo in vitro; y su uso para tratar una condicion causada por perdida de mielina o de oligodendrocitos.

Country Status (21)

Country	Link
US (1)	US8993320B2 (es)
EP (1)	EP2663638B1 (es)
JP (1)	JP5649745B2 (es)
KR (1)	KR102099807B1 (es)
CN (2)	CN103687941A (es)
AR (1)	AR084835A1 (es)
AU (2)	AU2012206411B2 (es)
BR (1)	BR112013017685A2 (es)
CA (1)	CA2821065C (es)
CL (1)	CL2013002029A1 (es)
DK (1)	DK2663638T3 (es)
EA (1)	EA034058B1 (es)
ES (1)	ES2732938T3 (es)
IL (1)	IL227361B (es)
MX (1)	MX364742B (es)
MY (1)	MY173219A (es)
PH (1)	PH12013501496B1 (es)
PL (1)	PL2663638T3 (es)
SG (1)	SG191729A1 (es)
TW (1)	TWI586805B (es)
WO (1)	WO2012095730A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003070171A2 (en)	2002-02-15	2003-08-28	Cornell Research Foundation, Inc.	Myelination of congenitally dysmyelinated forebrains using oligodendrocyte progenitor cells
CA2723382A1 (en)	2008-05-08	2009-11-12	University Of Rochester	Treating myelin diseases with optimized cell preparations
US10450546B2 (en)	2013-02-06	2019-10-22	University Of Rochester	Induced pluripotent cell-derived oligodendrocyte progenitor cells for the treatment of myelin disorders
IL281665B (en) *	2013-04-17	2022-07-01	Salk Inst For Biological Studi	Media compositions for neuronal cell culture
JP6615616B2 (ja) *	2014-01-21	2019-12-04	国立研究開発法人科学技術振興機構	アダルト型オリゴデンドロサイト前駆細胞の製造方法
CN105154386B (zh) *	2014-05-30	2018-04-24	中国人民解放军第二军医大学东方肝胆外科医院	人肝细胞长期维持和增殖传代培养的专用培养基和培养方法
KR101675123B1 (ko) *	2014-06-27	2016-11-14	연세대학교 산학협력단	Psa-ncam-양성 신경전구세포를 유효성분으로 포함하는 허혈성 질환 또는 신경염증 질환 치료용 조성물
KR101793722B1 (ko)	2014-08-25	2017-11-03	한국생명공학연구원	성상세포의 생산방법
KR102635212B1 (ko) *	2015-03-04	2024-02-13	메조블라스트 인터내셔널 에스에이알엘	중간엽 줄기 세포를 위한 세포 배양 방법
JP6780638B2 (ja) *	2015-03-30	2020-11-04	味の素株式会社	ヒト血清アルブミンを含む神経幹細胞増殖培地
CA2982959C (en) *	2015-04-16	2021-08-31	The Board Of Regents, The University Of Texas System	Cd133+ cells and method for expanding
JP6844953B2 (ja) *	2015-04-22	2021-03-17	公益財団法人東京都医学総合研究所	アルツハイマー病研究を標的にしたグリア細胞システム
US9724432B2 (en)	2015-04-30	2017-08-08	University Of Rochester	Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder
CN107921068A (zh) *	2015-06-26	2018-04-17	S生物医药公司	包含神经前体细胞的分泌蛋白质组作为有效成分的用于治疗缺血性疾病或神经炎症疾病的组合物
CA2995634A1 (en) *	2015-08-15	2017-02-23	Asterias Biotherapeutics, Inc.	Stem cell-derived oligodendrocyte progenitor cells for the treatment of white matter stroke
WO2017156762A1 (en)	2016-03-18	2017-09-21	Institute Of Biophysics, Chinese Academy Of Sciences	A cell culture medium and culture medium supplement
CA3019514A1 (en)	2016-03-30	2017-10-05	Asterias Biotherapeutics, Inc.	Oligodendrocyte progenitor cell compositions
CN106929474B (zh) *	2017-03-31	2021-09-14	北京恒峰铭成生物科技有限公司	一种m2巨噬细胞诱导剂
WO2018209022A2 (en)	2017-05-10	2018-11-15	University Of Rochester	Methods of treating neuropsychiatric disorders
KR101889228B1 (ko) *	2017-09-29	2018-08-16	연세대학교 산학협력단	Psa-ncam-양성 신경전구세포를 유효성분으로 포함하는 척수손상 치료용 조성물
CN107760649B (zh) *	2017-11-02	2021-03-30	北京全式金生物技术有限公司	一种用于人神经系统细胞培养和人多能性干细胞向神经系统细胞分化的营养添加剂
CN108070558B (zh) *	2017-11-24	2022-01-28	吉林省拓华生物科技有限公司	一种临床级神经干细胞的制备方法
KR101994640B1 (ko)	2018-03-16	2019-07-02	(주)메디노	신경줄기세포의 고효율 분리배양 방법
MA52540A (fr) *	2018-04-17	2021-02-24	Univ Case Western Reserve	Induction d'oligodendrocytes myélinisants dans des sphéroïdes corticaux humains
CN108624560B (zh) *	2018-06-01	2022-04-08	南京艾尔普再生医学科技有限公司	一种分化培养基及少突胶质前体细胞的制备方法
EP3853345A4 (en)	2018-09-19	2022-07-13	Lineage Cell Therapeutics, Inc.	Methods for differentiating pluripotent stem cells in dynamic suspension culture
CN120060141A (zh)	2019-01-23	2025-05-30	阿斯特里亚斯生物疗法股份有限公司	来自人多能干细胞的背源性少突胶质祖细胞
US20230123863A1 (en) *	2020-06-30	2023-04-20	National Yang-Ming University	A glia cell and neuron co-culture system and method
CN114540301B (zh) *	2020-11-20	2024-02-27	上海纽仁生物医药科技有限公司	少突胶质前体细胞亚群及其用途
IL316055A (en)	2022-04-15	2024-11-01	Aspen Neuroscience Inc	Methods of classifying the differentiation state of cells and related compositions of differentiated cells
CN117821382A (zh) *	2023-12-29	2024-04-05	广州赛莱拉干细胞科技股份有限公司	一种毛囊干细胞无血清培养基和培养方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1990003430A1 (en) *	1988-09-23	1990-04-05	Cetus Corporation	Cell culture medium for enhanced cell growth, culture longevity and product expression
DE19756864C5 (de) *	1997-12-19	2014-07-10	Oliver Brüstle	Neurale Vorläuferzellen, Verfahren zu ihrer Herstellung und ihre Verwendung zur Therapie von neuralen Defekten
US7504257B2 (en) *	2000-03-14	2009-03-17	Es Cell International Pte Ltd.	Embryonic stem cells and neural progenitor cells derived therefrom
GB2379447B (en) *	2000-05-17	2004-12-29	Geron Corp	Neural progenitor cell populations
EP1367899A4 (en) *	2001-02-14	2004-07-28	Leo T Furcht	TOTIPOTENT ADULT STEM CELLS, SOURCES OF SUCH CELLS, METHODS FOR OBTAINING AND MAINTAINING SAME, METHODS FOR DIFFERENTIATING THESE CELLS, METHODS OF USING SAME, AND CELLS DERIVED FROM THE ABOVE-MENTIONED CELLS
US9446073B2 (en) *	2005-05-15	2016-09-20	Biodontos, Llc	Non-lineage committed precursor cells from the dental papillary tissue of teeth
US20080153167A1 (en) *	2006-06-21	2008-06-26	The Trustees Of Columbia University In The City Of New York	In vivo amplification of neural progenitor cells
WO2008003042A2 (en) *	2006-06-28	2008-01-03	The University Of Medicine And Dentistry Of New Jersey	Amnion-derived stem cells and uses thereof
US20110236971A2 (en)	2007-09-25	2011-09-29	Maksym Vodyanyk	Generation of Clonal Mesenchymal Progenitors and Mesenchymal Stem Cell Lines Under Serum-Free Conditions
EP2379711B8 (en)	2008-12-23	2017-03-22	BOCO Silicon Valley, Inc.	Target populations of oligodendrocyte precursor cells and methods of making and using same

2012
- 2012-01-12 US US13/349,089 patent/US8993320B2/en active Active
- 2012-01-12 AR ARP120100101A patent/AR084835A1/es not_active Application Discontinuation
- 2012-01-12 CN CN201280004915.9A patent/CN103687941A/zh active Pending
- 2012-01-12 WO PCT/IB2012/000030 patent/WO2012095730A1/en not_active Ceased
- 2012-01-12 CA CA2821065A patent/CA2821065C/en active Active
- 2012-01-12 PL PL12701024T patent/PL2663638T3/pl unknown
- 2012-01-12 DK DK12701024.7T patent/DK2663638T3/da active
- 2012-01-12 MX MX2013008208A patent/MX364742B/es active IP Right Grant
- 2012-01-12 CN CN201811129309.5A patent/CN109749996A/zh active Pending
- 2012-01-12 MY MYPI2013701211A patent/MY173219A/en unknown
- 2012-01-12 EP EP12701024.7A patent/EP2663638B1/en active Active
- 2012-01-12 TW TW101101245A patent/TWI586805B/zh active
- 2012-01-12 PH PH1/2013/501496A patent/PH12013501496B1/en unknown
- 2012-01-12 AU AU2012206411A patent/AU2012206411B2/en active Active
- 2012-01-12 EA EA201390801A patent/EA034058B1/ru not_active IP Right Cessation
- 2012-01-12 JP JP2013548899A patent/JP5649745B2/ja active Active
- 2012-01-12 BR BR112013017685A patent/BR112013017685A2/pt not_active Application Discontinuation
- 2012-01-12 KR KR1020137018381A patent/KR102099807B1/ko active Active
- 2012-01-12 ES ES12701024T patent/ES2732938T3/es active Active
- 2012-01-12 SG SG2013045810A patent/SG191729A1/en unknown
2013
- 2013-07-07 IL IL227361A patent/IL227361B/en active IP Right Grant
- 2013-07-12 CL CL2013002029A patent/CL2013002029A1/es unknown
2017
- 2017-08-18 AU AU2017216594A patent/AU2017216594B2/en active Active

Also Published As

Publication number	Publication date
PL2663638T3 (pl)	2020-02-28
AR084835A1 (es)	2013-06-26
WO2012095730A1 (en)	2012-07-19
AU2012206411A1 (en)	2013-07-04
TWI586805B (zh)	2017-06-11
MX2013008208A (es)	2013-10-17
EP2663638B1 (en)	2019-03-27
US8993320B2 (en)	2015-03-31
NZ712598A (en)	2016-03-31
AU2017216594A1 (en)	2017-09-07
KR102099807B1 (ko)	2020-04-14
DK2663638T3 (da)	2019-07-08
IL227361B (en)	2018-03-29
US20120177614A1 (en)	2012-07-12
CN109749996A (zh)	2019-05-14
AU2012206411B2 (en)	2017-05-18
NZ611902A (en)	2016-01-29
TW201237169A (en)	2012-09-16
CA2821065A1 (en)	2012-07-19
BR112013017685A2 (pt)	2016-10-11
ES2732938T3 (es)	2019-11-26
MX364742B (es)	2019-05-07
EP2663638A1 (en)	2013-11-20
JP2014503219A (ja)	2014-02-13
JP5649745B2 (ja)	2015-01-07
EA034058B1 (ru)	2019-12-23
CN103687941A (zh)	2014-03-26
KR20140071512A (ko)	2014-06-11
CA2821065C (en)	2021-05-18
IL227361A0 (en)	2013-09-30
EA201390801A1 (ru)	2014-06-30
PH12013501496B1 (en)	2023-05-24
SG191729A1 (en)	2013-08-30
PH12013501496A1 (es)	2013-09-16
MY173219A (en)	2020-01-07
AU2017216594B2 (en)	2020-01-23

Publication	Publication Date	Title
CL2013002029A1 (es)	2014-05-09	Celula progenitora y no diferenciada neural humana expandible aislada; composicion que la comprende; metodo de cultivo in vitro; dicho cultivo in vitro; y su uso para tratar una condicion causada por perdida de mielina o de oligodendrocitos.
BR112015030946A2 (pt)	2017-07-25	composição compreendendo uma célula ß pancreática não-nativa, método de diferenciação de células progenitoras em células ß pancreáticas in vitro e uso de uma célula ß pancreática não-nativa
AR091388A1 (es)	2015-02-04	Diferenciacion de celulas madres embrionicas humanas en celulas endocrinas pancreaticas
GT201400147A (es)	2015-04-06	Pirimidinas y triazinas fusionadas sustituidas y su uso
BRPI1013771A2 (pt)	2016-04-05	"células-tronco mesenquimais projetadas e método de uso das mesmas para tratar tumores."
DOP2011000384A (es)	2012-12-15	Metodos para el cultivo de celulas madre y progenitoras
PL3421601T3 (pl)	2020-06-01	Wytwarzanie i stosowanie zsyntetyzowanego in vitro ssRNA do wprowadzania do ssaczych komórek w celu indukcji efektu biologicznego lub biochemicznego
CO7010785A2 (es)	2014-07-31	Anticuerpos específicos para trop-2 y sus usos
NI201300080A (es)	2014-02-25	Formas sólidas de 3 - ( 5 - amino - 2 - metil - 4 - oxo - 4h - quinazolin - 3 - il ) - piperidin - 2, 6 - diona, y sus composiciones farmacéuticas y usos
GT201400033A (es)	2015-01-15	Pirimidinas anilladas sustituidas y uso de las mismas
BR112013001423A2 (pt)	2016-05-24	método, método in vitro, uso e kit útil para realizar o método
UY34204A (es)	2013-02-28	?Proceso para preparar poliuretano poliureas que contienen cadenas laterales y dispersiones acuosas de las mismas?.
CL2013001975A1 (es)	2014-03-07	Dominio variable individual de inmunoglobulina anti-tgfbetarii; acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica; y su uso para tratar una enfermedad asociada con la señalizacion de tgfbeta.
EP3070163A4 (en)	2017-06-28	Method for preparing induced pluripotent stem cell, composition used in method, and uses thereof
CL2013000238A1 (es)	2014-03-28	Uso de inhibores de la succinato deshidrogenasa y/o inhibidores del complejo iii para mejorar la relacion entre microorganismos dañinos y beneficiosos.
CO6821883A2 (es)	2013-12-31	Nuevos moduladores y métodos para su uso
BR112014002718A2 (pt)	2017-06-13	célula, população de célula, composição farmacêutica e kit para uso no tratamento de uma doença de degeneraçãoretinal
WO2013109856A3 (en)	2013-11-14	Methods of using fgf19 modulators
BR112012016229A2 (pt)	2017-03-07	método para melhorar a sobrevida livre de progressão, método in vitro, kit, uso de um oligonucleotídeo ou polipetídeo e uso de bevacizumab
CL2014001181A1 (es)	2014-10-03	Kit para el cultivo mejorado de células in vitro que comprende sustitucion de suero y factores labiles
BR112014013172A2 (pt)	2017-06-13	extratos de maesa japonica e métodos de uso
BR112014009500A2 (pt)	2017-04-18	método in vitro para a liberação de um composto de vitamina d, método in vitro para medição de um composto de vitamina d e uso de uma composição reagente
ECSP13012997A (es)	2013-12-31	Antídotos anticoagulantes
CL2011002689A1 (es)	2012-04-27	Microcapsulas que comprenden una suspension de celulas hepaticas en contacto con eritropoyetina estimulante de celulas hepaticas; metodo para preparar microcapsulas; y uso de las microcapsulas para tratar enfermedad hepatica.
BR112014013990A2 (pt)	2017-06-13	retardador hidrodinâmico desconectável e método para controlar o mesmo